In recent years, notable advances have been made in diagnosing and treating breast cancer. However, its recurrence continues ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Middle aged woman dressed in pink showing strength and smiling in a park. Fight against ...

Add Yahoo as a preferred source to see more of our stories on Google. New prospective sub-study analysis data presented by Abbott at the 2026 American Society of Clinical Oncology (ASCO) meeting has ...

Real-world survival outcomes with pembrolizumab plus chemotherapy in advanced triple-negative breast cancer: Multicenter evidence from Poland, the Czech Republic, and Slovakia. This is an ASCO Meeting ...

Previous work showed that RNase H2 activity helps triple-negative breast cancer (TNBC) cells manage high levels of replication stress, offering new therapeutic insights. Researchers from The ...

A Daiichi Sankyo and AstraZeneca drug is now approved as a first-line treatment for a particularly difficult-to-treat type of breast cancer, bringing a new targeted therapy to patients that’s ...

Adding atezolizumab immunotherapy to capecitabine for the adjuvant treatment of triple-negative breast cancer (TNBC) in patients with residual disease after neoadjuvant chemotherapy does not offer a ...

Recurrent pericarditis occurs when inflammation of the pericardium — the protective sac around your heart — returns after 4 weeks of being symptom-free. About 15% to 30% of people with pericarditis ...

I’ve spent much of my career thinking about one central question in oncology: how do we give patients clearer answers about their cancer? In the clinic, those questions are often simple but profound.

For patients with early-stage triple-negative breast cancer (TNBC), finishing chemotherapy and surgery should feel like the end of the hardest chapter. But for many, it marks the beginning of a ...

A global, multicenter phase III trial, TROPION-Breast02, led by a senior medical oncologist and researcher from the National Cancer Centre Singapore, has demonstrated a significant breakthrough in ...